Heska Corp (NASDAQ:HSKA) Director Bonnie J. Trowbridge sold 5,000 shares of the stock in a transaction that occurred on Tuesday, May 29th. The stock was sold at an average price of $101.01, for a total value of $505,050.00. Following the completion of the transaction, the director now directly owns 6,249 shares in the company, valued at approximately $631,211.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Heska opened at $102.03 on Friday, according to Marketbeat.com. The firm has a market cap of $761.55 million, a price-to-earnings ratio of 49.29 and a beta of 0.80. Heska Corp has a 12-month low of $56.59 and a 12-month high of $115.00.
Heska (NASDAQ:HSKA) last announced its earnings results on Friday, May 4th. The medical research company reported $0.28 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.12). Heska had a net margin of 5.57% and a return on equity of 13.30%. The company had revenue of $32.77 million for the quarter, compared to the consensus estimate of $31.65 million. equities research analysts forecast that Heska Corp will post 1.68 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the company. Quantitative Systematic Strategies LLC purchased a new stake in shares of Heska during the 4th quarter valued at $206,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Heska during the 4th quarter valued at $209,000. Envestnet Asset Management Inc. lifted its holdings in shares of Heska by 85.8% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,755 shares of the medical research company’s stock valued at $218,000 after purchasing an additional 1,272 shares during the last quarter. MetLife Investment Advisors LLC purchased a new stake in shares of Heska during the 4th quarter valued at $263,000. Finally, Virginia Retirement Systems ET AL purchased a new stake in shares of Heska during the 1st quarter valued at $411,000. Hedge funds and other institutional investors own 89.16% of the company’s stock.
HSKA has been the topic of several research analyst reports. B. Riley dropped their price objective on Heska from $93.00 to $77.00 and set a “neutral” rating on the stock in a research note on Thursday, March 1st. Canaccord Genuity reissued a “buy” rating and issued a $95.00 price objective on shares of Heska in a research note on Thursday, March 1st. BidaskClub raised Heska from a “strong sell” rating to a “sell” rating in a research report on Friday, March 9th. Benchmark increased their target price on Heska from $120.00 to $143.00 and gave the company a “buy” rating in a research report on Monday, May 21st. They noted that the move was a valuation call. Finally, ValuEngine raised Heska from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $115.25.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.